Search
DDP733
go.drugbank.com/drugs/DB05049InvestigationalDDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368InvestigationalAntibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). … Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
GS030-DP
go.drugbank.com/drugs/DB17847InvestigationalGS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. … It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
AC-003
go.drugbank.com/drugs/DB22691InvestigationalAC-003 is a selective, oral small-molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1). … [L53458] It is being investigated for the treatment of acute graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF).[L53458]
Salts: Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)-imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate hydrochlorideSynonyms: Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)- imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate, Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)-imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylateCanfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
T487
go.drugbank.com/drugs/DB05474ExperimentalT487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.
BBIBP-CorV
go.drugbank.com/drugs/DB15807InvestigationalBBIBP-CorV vaccine contains a SARS-CoV-2 strain inactivated inside Vero Cells. … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
BB-301
go.drugbank.com/drugs/DB17011Investigational[A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062] … BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide
go.drugbank.com/drugs/DB06945ExperimentalThese are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. … This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.
Enlonstobart
go.drugbank.com/drugs/DB21890InvestigationalEnlonstobart is a recombinant and fully-humanized immunoglobulin G4 monoclonal antibody. … [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.